# PD of VAY736 in Patients With Primary Sjögren's Syndrome

> **NCT02149420** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** VAY736
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02149420
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-23
- **Primary completion:** 2018-02-07
- **Final completion:** 2018-02-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149420, "PD of VAY736 in Patients With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02149420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*